Clik here to view.
OPKO Announces Launch of 4Kscore Test for Prostate Cancer
MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announced the availability of the 4Kscore Test through its CLIA-accredited OPKO Lab in Nashville, TN. The laboratory-developed test is designed to...
View ArticleClik here to view.
AUA Accepts 4Kscore Test Clinical Study on Prostate Cancer Screening
OPKO Presents 4Kscore Test Clinical Study at the American Urological Association Plenary SessionMIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) announced the results of the data from its blinded,...
View ArticleClik here to view.
OPKO Launches the 4Kscore Test in Europe
MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the European launch of the 4Kscore Test, the only blood test that accurately identifies risk for aggressive prostate cancer,...
View ArticleClik here to view.
OPKO Health Supports National Prostate Cancer Council Legislation
MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK) is pleased to lend its support to the legislation introduced in the United States Senate onSeptember 16, 2014 by Senators Jeff Sessions (R-AL) and...
View ArticleClik here to view.
OPKO Lab Receives Accreditation From College of American Pathologist
CAP Accreditation is Awarded to Clinical Laboratories Meeting the Highest Standards of Excellence in Quality Laboratory Practices Nashville, TN and Miami, FL – March 18, 2015 -- OPKO Health, Inc....
View ArticleClik here to view.
OPKO Announces Publication of ProtecT Study Using Kallikrein Biomarkers in...
MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the online publication of a study entitled "Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers...
View ArticleClik here to view.
New Blood Test Helps You Avoid Unnecessary Prostate Cancer Biopsies
Can be used in conjunction with PSA blood testA new screening tool for prostate cancer has been shown to offer better accuracy than the test currently used by most physicians in the United States. The...
View ArticleClik here to view.
OPKO Announces Publication of Study Using Kallikrein Biomarkers of the...
MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the online publication of a study entitled "A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in...
View ArticleClik here to view.
OPKO 4Kscore Recommended in National Comprehensive Cancer Network Guidelines...
MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the decision of the National Comprehensive Cancer Network (NCCN) to include 4Kscore® as a recommended test in the 2015 NCCN...
View ArticleClik here to view.
OPKO Lab Signs Contracts with Leading Preferred Provider Networks for...
MIAMI, Aug 19, 2015 (BUSINESS WIRE) -- OPKO Health, Inc. OPK, -0.24% today announced that it has entered into agreements with Stratose, Three Rivers Provider Network and Fortified Provider Network for...
View ArticleClik here to view.
Dr. Frost Discusses Bio-Reference Acquisition, Impact of 4Kscore Test with...
OPKO Health CEO Dr. Phillip Frost visited Jim Cramer on Mad Money September 25, 2015, to explain the recent acquisition of Bio-Reference Laboratories and the impact it expects to have on our overall...
View ArticleClik here to view.
Opko Health Research Coverage Started at JPMorgan Chase & Co. (OPK)
Article Published in the Dakota Financial News, October 16, 2015
View ArticleClik here to view.
4Kscore Might Reduce Unnecessary Prostate Biopsies
ORLANDO—The 4Kscore, an algorithmic analysis of data from a blood test that combines four kallikrein assays with clinical information to identify the probability of high-grade prostate tumors, could...
View ArticleClik here to view.
Study Confirms 4Kscore Accurately Predicts High-Grade Prostate Cancer
By Anna Azvolinsky, PhD
View ArticleClik here to view.
New Blood Test Helps You Avoid Unnecessary Prostate Cancer Biopsies
Can be used in conjunction with PSA blood testMay 6, 2015 / By Urinary & Kidney Team at Cleveland Clinic
View ArticleClik here to view.
New Test Reducing The Number Of Invasive Prostate Biopsies
MIAMI (CBSMiami) – Every year more than one million men have a prostate biopsy, an invasive procedure that involves needles. It turns out a majority of those biopsies reveal if a patient has no...
View ArticleClik here to view.
Study Demonstrates OPKO's 4Kscore Test Reduces Unnecessary Prostate Biopsies...
4Kscore Test Results Significantly Influenced Physician-Patient Shared Decision-Making in Clinical Practice and Led to a 64.6% Reduction in Prostate Biopsies
View ArticleClik here to view.
Clik here to view.
OPKO Announces Publication of Study Using Kallikrein Biomarkers of the...
MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the online publication of a study entitled "A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in...
View ArticleClik here to view.
New Blood Test Helps You Avoid Unnecessary Prostate Cancer Biopsies
Can be used in conjunction with PSA blood testA new screening tool for prostate cancer has been shown to offer better accuracy than the test currently used by most physicians in the United States. The...
View Article